Search details
1.
Biology and Clinical Implications of the 19q13 Aggressive Prostate Cancer Susceptibility Locus.
Cell
; 174(3): 576-589.e18, 2018 07 26.
Article
in English
| MEDLINE | ID: mdl-30033361
2.
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.
N Engl J Med
; 386(12): 1132-1142, 2022 03 24.
Article
in English
| MEDLINE | ID: mdl-35179323
3.
Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS.
Oncologist
; 2024 Feb 23.
Article
in English
| MEDLINE | ID: mdl-38394384
4.
Screening history and risk of death from prostate cancer: a nested case-control study within the screening arm of the Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC).
Cancer Causes Control
; 35(4): 695-703, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-38063980
5.
Which men benefit from prostate cancer screening? Prostate cancer mortality by subgroup in the European Randomised Study of Screening for Prostate Cancer.
BJU Int
; 2024 May 09.
Article
in English
| MEDLINE | ID: mdl-38725182
6.
Expected impact of MRI-targeted biopsy interreader variability among uropathologists on ProScreen prostate cancer screening trial: a pre-trial validation study.
World J Urol
; 42(1): 217, 2024 Apr 06.
Article
in English
| MEDLINE | ID: mdl-38581590
7.
Prostate Cancer Screening With PSA, Kallikrein Panel, and MRI: The ProScreen Randomized Trial.
JAMA
; 331(17): 1452-1459, 2024 05 07.
Article
in English
| MEDLINE | ID: mdl-38581254
8.
Antidiabetic drugs, glycemic control and risk of benign prostatic hyperplasia.
Prostate
; 83(3): 246-258, 2023 02.
Article
in English
| MEDLINE | ID: mdl-36325820
9.
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide.
N Engl J Med
; 383(11): 1040-1049, 2020 09 10.
Article
in English
| MEDLINE | ID: mdl-32905676
10.
Anti-epileptic drugs and prostate cancer-specific mortality compared to non-users of anti-epileptic drugs in the Finnish Randomized Study of Screening for Prostate Cancer.
Br J Cancer
; 127(4): 704-711, 2022 09.
Article
in English
| MEDLINE | ID: mdl-35505251
11.
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.
N Engl J Med
; 380(13): 1235-1246, 2019 03 28.
Article
in English
| MEDLINE | ID: mdl-30763142
12.
Improved renal cancer prognosis among users of drugs targeting renin-angiotensin system.
Cancer Causes Control
; 33(2): 313-320, 2022 Feb.
Article
in English
| MEDLINE | ID: mdl-34921656
13.
Lower Urinary Tract Symptoms and Mortality among Finnish Men: The Roles of Symptom Severity and Bother.
J Urol
; 207(6): 1285-1294, 2022 06.
Article
in English
| MEDLINE | ID: mdl-35470712
14.
Antiepileptic drugs and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.
Int J Cancer
; 149(2): 307-315, 2021 07 15.
Article
in English
| MEDLINE | ID: mdl-33634851
15.
Number of screening rounds attended and incidence of high-risk prostate cancer in the Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC).
Cancer
; 127(2): 188-192, 2021 01 15.
Article
in English
| MEDLINE | ID: mdl-33048394
16.
Bias-corrected estimates of effects of PSA screening decisions on the risk of prostate cancer diagnosis and death: Analysis of the Finnish randomized study of screening for prostate cancer.
Int J Cancer
; 145(3): 632-638, 2019 08 01.
Article
in English
| MEDLINE | ID: mdl-30653262
17.
Risk Prediction of Prostate Cancer with Single Nucleotide Polymorphisms and Prostate Specific Antigen.
J Urol
; 201(3): 486-495, 2019 03.
Article
in English
| MEDLINE | ID: mdl-30366021
18.
Prostate cancer risk regions at 8q24 and 17q24 are differentially associated with somatic TMPRSS2:ERG fusion status.
Hum Mol Genet
; 25(24): 5490-5499, 2016 12 15.
Article
in English
| MEDLINE | ID: mdl-27798103
19.
Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases.
Br J Cancer
; 119(3): 347-356, 2018 08.
Article
in English
| MEDLINE | ID: mdl-29988112
20.
Bladder Cancer Survival of Men Receiving 5α-Reductase Inhibitors.
J Urol
; 200(4): 743-748, 2018 10.
Article
in English
| MEDLINE | ID: mdl-29730200